Peter Lamb - 15 Dec 2022 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
EVP, Scientific Strategy & CSO
Signature
/s/ Nina Ayer, Attorney in Fact
Issuer symbol
EXEL
Transactions as of
15 Dec 2022
Net transactions value
-$233,600
Form type
4
Filing time
16 Dec 2022, 19:09:47 UTC
Previous filing
17 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $84,000 +20,000 +4.9% $4.20 430,958 15 Dec 2022 Direct F1
transaction EXEL Common Stock Sale $317,600 -20,000 -4.6% $15.88 410,958 15 Dec 2022 Direct F2, F3
holding EXEL Common Stock 17,105 15 Dec 2022 By 401(k) F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -20,000 -50% $0.000000 20,000 15 Dec 2022 Common Stock 20,000 $4.20 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 120,383 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
F2 The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2022.
F3 Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $15.71 to $16.07. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.
F4 Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of December 14, 2022.
F5 The option, representing the right to purchase a total of 40,000 shares of Exelixis, Inc. common stock, became fully exercisable on February 11, 2020.